These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 17237265

  • 1. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 2. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
    Kim J, Guan J, Chang I, Chen X, Han D, Wang CY.
    Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
    [Abstract] [Full Text] [Related]

  • 3. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P, Kawada J, Pesnicak L, Cohen JI.
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C.
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C.
    Clin Cancer Res; 2008 Jul 01; 14(13):4175-85. PubMed ID: 18593997
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S.
    Blood; 2003 Nov 15; 102(10):3765-74. PubMed ID: 12893773
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
    Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.
    Mol Cancer Res; 2011 Feb 15; 9(2):183-94. PubMed ID: 21224428
    [Abstract] [Full Text] [Related]

  • 13. Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer.
    Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C.
    Clin Cancer Res; 2009 Oct 01; 15(19):5974-84. PubMed ID: 19789307
    [Abstract] [Full Text] [Related]

  • 14. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB.
    Cancer Res; 2005 Oct 15; 65(20):9555-65. PubMed ID: 16230421
    [Abstract] [Full Text] [Related]

  • 15. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
    Gao N, Dai Y, Rahmani M, Dent P, Grant S.
    Mol Pharmacol; 2004 Oct 15; 66(4):956-63. PubMed ID: 15235103
    [Abstract] [Full Text] [Related]

  • 16. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
    Jane EP, Premkumar DR, Pollack IF.
    Mol Cancer Ther; 2011 Jan 15; 10(1):198-208. PubMed ID: 21220502
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.
    Blood; 2009 Jul 30; 114(5):1046-52. PubMed ID: 19436050
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C, Li R, Grandis JR, Johnson DE.
    Mol Cancer Ther; 2008 Jun 30; 7(6):1647-55. PubMed ID: 18566236
    [Abstract] [Full Text] [Related]

  • 19. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
    Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S.
    Br J Haematol; 2007 Nov 30; 139(3):385-97. PubMed ID: 17910628
    [Abstract] [Full Text] [Related]

  • 20. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE, Rundall BK, Jones DR.
    J Thorac Cardiovasc Surg; 2004 Nov 30; 128(5):740-8. PubMed ID: 15514602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.